P1.13-28 The Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy

M. Yang; N. Zhang; H. Xing; J. Liu

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P1.13-28 The Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy

【24h】

P1.13-28 The Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy

机译：P1.13-28功能性MDM4遗传多甲语作为预后生物标志物，用于晚期肺腺癌患者的生存患者对EGFR-TKIS治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2018年第10期|共1页
作者
M. Yang; N. Zhang; H. Xing; J. Liu;
展开▼
作者单位

Shandong Cancer Hospital Affiliated To Shandong University Jinan/CN;

Department of Radiation Oncology Shandong Cancer Hospital Affiliated To Shandong University Jinan;

Shandong University Jinan/CN;

Shandong Cancer Hospital Affiliated To Shandong University Jinan/china Jinan/CN;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P1.13-28 The Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy [J] . M. Yang, N. Zhang, H. Xing, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P1.13-28功能性MDM4遗传多甲语作为预后生物标志物，用于晚期肺腺癌患者的生存患者对EGFR-TKIS治疗
2. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients [J] . Wang Y., Li R. Q., Ai Y. Q., Clinical & translational oncology : . 2015,第9期

机译：外显子19缺失与一线化疗后以EGFR-TKIs作为二线治疗的突变EGFR晚期EGFR晚期肺癌患者的更好生存结果相关：回顾性分析128例患者
3. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients [J] . Y. Wang, R. Q. Li, Y. Q. Ai, Clinical and Translational Oncology . 2015,第9期

机译：外显子19缺失与一线化疗后以EGFR-TKIs作为二线治疗的突变EGFR的晚期EGFR在晚期肺腺癌中具有更好的生存结局：回顾性分析128例患者
4. Immune based prognostic biomarkers for multiple anticancer therapies in lung adenocarcinoma [C] . Kritika Karri, Dhundy R Bastola IEEE International Conference on Bioinformatics and Biomedicine . 2016

机译：基于免疫的预后生物标志物，用于肺腺癌的多种抗癌治疗
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations [O] . Ruiguang Zhang, Yan Li, Xiu Nie, 2016

机译：免疫组化标记物对中国EGFR突变晚期肺腺癌患者EGFR-TKI治疗的预后意义
7. P1.13-28 The Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy [O] . M. Yang, N. Zhang, H. Xing, 2018

机译：P1.13-28功能性MDM4遗传多甲语作为预后生物标志物，用于晚期肺腺癌患者的生存患者对EGFR-TKIS治疗

P1.13-28 The Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy

著录项

相似文献

相关主题

期刊订阅